Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment

Clin Exp Dermatol. 2023 Apr 27;48(5):558-559. doi: 10.1093/ced/llad040.

Authors

Niccolò Gori^{1

2}, Elena Ippoliti^{1

2}, Flaminia Antonelli^{1

2}, Ketty Peris^{1

2}, Andrea Chiricozzi^{1

2}

Affiliations

¹ Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
² Dermatologia, Dipartimento Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

PMID: 36724039
DOI: 10.1093/ced/llad040

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized / therapeutic use
Dermatitis, Atopic* / drug therapy
Dermatitis, Atopic* / pathology
Humans
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
upadacitinib
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal